Physician profile
David Raben
NPI 1982711727
$61,065.74
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $2,175.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $46,544.94 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $5,027.96 | 2019-2020 | |
| Regeneron Pharmaceuticals, INC. | $3,998.63 | 2019 | |
| Emd Serono, INC. | $2,163.69 | 2019-2020 | |
| Genentech, INC. | $1,310.58 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,203.00 | 2019 | |
| F. Hoffmann-La Roche Ag | $551.80 | 2019 | |
| Merck Sharp & Dohme LLC | $149.14 | 2019 | |
| Roche Products Limited | $116.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Raben listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.